Rhythm Pharmaceuticals Wins FDA Approval for IMCIVREE in Acquired Hypothalamic Obesity Launch



Rhythm Pharmaceuticals (NASDAQ:RYTM) announced that the U.S. Food and Drug Administration has approved IMCIVREE (setmelanotide) for patients with acquired hypothalamic obesity, according to executives on a company conference call held following the approval news.

FDA approval and label details
Chie



Source link

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *